Figure 1: Design Variables to Be Considered When Developing Biomaterial Applications for MI and PAD

2019-06-11T07:04:09Z (GMT) by Melissa J. Hernandez Karen L. Christman
To successfully translate biomaterials to the clinic, specific design criteria must be considered to ensure that the final product remains biocompatible while maintaining its full therapeutic efficacy. Extensive engineering of a biomaterial can maximize therapeutic benefits, but these benefits must counterbalance accompanied costs and manufacturing difficulties. MI = myocardial infarction; miRNA = microribonucleic acid; PAD = peripheral artery disease.